welcome
Investor's Business Daily

Investor's Business Daily

Health

Health

Biogen beats first-quarter expectations, but shares are down in premarket action

Investor's Business Daily
Summary
Nutrition label

82% Informative

Biogen beat Wall Street expectations for first-quarter sales.

Leqembi and Skyclarys brought in $124 million in sales, growing almost 59% year over year .

Sales of key MS drugs Tysabri and Tecfidera beat expectations.

Biogen cut its earnings expectations to $ 14.50 to $ 15.50 per share.

VR Score

89

Informative language

95

Neutral language

72

Article tone

formal

Language

English

Language complexity

41

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

detected

Known propaganda techniques

not detected

Time-value

short-lived

Affiliate links

no affiliate links